Dexmedetomidine vs Midazolam for Sedation of Critically Ill PatientsA Randomized Trial

CONTEXT: Gamma-aminobutyric acid receptor agonist medications are the most commonly used sedatives for intensive care unit (ICU) patients, yet preliminary evidence indicates that the alpha (2) agonist dexmedetomidine may have distinct advantages. OBJECTIVE: To compare the efficacy and safety of prolonged sedation with dexmedetomidine vs midazolam for mechanically ventilated patients. DESIGN, SETTING, AND PATIENTS: Prospective, double-blind, randomized trial conducted in 68 centers in 5 countries between March 2005 and August 2007 among 375 medical/surgical ICU patients with expected mechanical ventilation for more than 24 hours. Sedation level and delirium were assessed using the Richmond Agitation-Sedation Scale (RASS) and the Confusion Assessment Method for the ICU. INTERVENTIONS: Dexmedetomidine (0. 2-1. 4 microg/kg per hour n = 244) or midazolam (0. 02-0. 1 mg/kg per hour n = 122) titrated to achieve light sedation (RASS scores between -2 and +1) from enrollment until extubation or 30 days. MAIN OUTCOME MEASURES: Percentage of time within target RASS range. Secondary end points included prevalence and duration of delirium, use of fentanyl and open-label midazolam, and nursing assessments. Additional outcomes included duration of mechanical ventilation, ICU length of stay, and adverse events. RESULTS: There was no difference in percentage of time within the target RASS range (77. 3% for dexmedetomidine group vs 75. 1% for midazolam group; difference, 2. 2% 95% confidence interval CI, -3. 2% to 7. 5%; P =. 18). The prevalence of delirium during treatment was 54% (n = 132/244) in dexmedetomidine-treated patients vs 76. 6% (n = 93/122) in midazolam-treated patients (difference, 22. 6% 95% CI, 14% to 33%; P <. 001). Median time to extubation was 1. 9 days shorter in dexmedetomidine-treated patients (3. 7 days 95% CI, 3. 1 to 4. 0 vs 5. 6 days 95% CI, 4. 6 to 5. 9; P =. 01), and ICU length of stay was similar (5. 9 days 95% CI, 5. 7 to 7. 0 vs 7. 6 days 95% CI, 6. 7 to 8. 6; P =. 24). Dexmedetomidine-treated patients were more likely to develop bradycardia (42. 2% 103/244 vs 18. 9% 23/122; P <. 001), with a nonsignificant increase in the proportion requiring treatment (4. 9% 12/244 vs 0. 8% 1/122; P =. 07), but had a lower likelihood of tachycardia (25. 4% 62/244 vs 44. 3% 54/122; P <. 001) or hypertension requiring treatment (18. 9% 46/244 vs 29. 5% 36/122; P =. 02). CONCLUSIONS: There was no difference between dexmedetomidine and midazolam in time at targeted sedation level in mechanically ventilated ICU patients. At comparable sedation levels, dexmedetomidine-treated patients spent less time on the ventilator, experienced less delirium, and developed less tachycardia and hypertension. The most notable adverse effect of dexmedetomidine was bradycardia. TRIAL REGISTRATION: clinicaltrials. gov Identifier: NCT00216190 Published online February 2, 2009 (doi: 10. 1001/jama. 2009. 56).